

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Savient Pharma Holdings, Inc.	08/04/2006
RECEIVING PARTY DATA	
Name:	INGLEBY (1705) Limited
Street Address:	Rosemont House, Yorkdale Industrial Park, Braithwaite Street
City:	Leeds
State/Country:	UNITED KINGDOM
Postal Code:	LS11 9XE
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	6127425
Application Number:	60745653
CORRESPONDENCE DATA	
Fax Number:	(312)577-4741
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	312-902-5665
Email:	becky.williams@kattenlaw.com
Correspondent Name:	Becky A. Williams
Address Line 1:	525 W. Monroe Street
Address Line 4:	Chicago, ILLINOIS 60661
ATTORNEY DOCKET NUMBER:	336537-1
NAME OF SUBMITTER:	Becky A. Williams
Total Attachments: 5 source=Savient patent assignment#page1.tif source=Savient patent assignment#page2.tif source=Savient patent assignment#page3.tif	

CH \$80.00 6127425

500140621

PATENT  
REEL: 018132 FRAME: 0593

source=Savient patent assignment#page4.tif  
source=Savient patent assignment#page5.tif

## ASSIGNMENT OF PATENTS


Savient Pharma Holdings, Inc., a Delaware corporation (the "Seller"), located at 103 Foulk Road, Suite 273, Wilmington, Delaware 19803, hereby assigns, effective as of the date hereof, to INGLEBY (1705) Limited, a private limited company incorporated under the laws of England and Wales (the "Buyer"), located at Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LS11 9XE, United Kingdom, the entire right, title and interest for the United States of America and its territorial possessions, and all foreign countries including all rights of priority, in the inventions disclosed in the patents and patent applications identified on Schedule A and said patents and patent applications ("Patent Rights"), and in and to all Letters Patents of the United States and all foreign countries which may or shall be granted on said Patent Rights, or any parts thereof, or any divisionals, continuations, continuations-in-part, reissues, renewals and extensions thereof or other applications based in whole or in part thereon. The Seller also transfers its entire, right, title and interest to the Buyer to recover for past infringement.

Savient Pharma Holdings, Inc. does hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said inventions or applications based thereon to the Buyer, its successors and assigns. The Buyer hereby accepts said Assignment.

Neither the representations and warranties nor the rights, remedies, liabilities or obligations of any party under the Purchase and Sale Agreement dated as of the date hereof, among Savient Pharmaceuticals, Inc. and the Seller, on the one hand, and the Buyer, on the other hand, shall be deemed to be enlarged, modified or altered in any way by this instrument.

Witness my hand and seal this 4 day of August, 2006.

SAVIENT PHARMA HOLDINGS, INC.

  
Name: PHILIP D. HERTZ  
Title: DIRECTOR

Witness my hand and seal this \_\_\_\_ day of August, 2006.

INGLEBY (1705) LIMITED

\_\_\_\_\_  
Name:  
Title:

## ASSIGNMENT OF PATENTS

Savient Pharma Holdings, Inc., a Delaware corporation (the "Seller"), located at 103 Foulk Road, Suite 273, Wilmington, Delaware 19803, hereby assigns, effective as of the date hereof, to INGLEBY (1705) Limited, a private limited company incorporated under the laws of England and Wales (the "Buyer"), located at Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LS11 9XE, United Kingdom, the entire right, title and interest for the United States of America and its territorial possessions, and all foreign countries including all rights of priority, in the inventions disclosed in the patents and patent applications identified on Schedule A and said patents and patent applications ("Patent Rights"), and in and to all Letters Patents of the United States and all foreign countries which may or shall be granted on said Patent Rights, or any parts thereof, or any divisionals, continuations, continuations-in-part, reissues, renewals and extensions thereof or other applications based in whole or in part thereon. The Seller also transfers its entire, right, title and interest to the Buyer to recover for past infringement.

Savient Pharma Holdings, Inc. does hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said inventions or applications based thereon to the Buyer, its successors and assigns. The Buyer hereby accepts said Assignment.

Neither the representations and warranties nor the rights, remedies, liabilities or obligations of any party under the Purchase and Sale Agreement dated as of the date hereof, among Savient Pharmaceuticals, Inc. and the Seller, on the one hand, and the Buyer, on the other hand, shall be deemed to be enlarged, modified or altered in any way by this instrument.

Witness my hand and seal this 4 day of August, 2006.

SAVIENT PHARMA HOLDINGS, INC.

\_\_\_\_\_  
Name:  
Title:

Witness my hand and seal this 4 day of August, 2006.

INGLEBY (1705) LIMITED



\_\_\_\_\_  
Name: John B. T. T.  
Title: Director

**Schedule A**

**Assignment of Patents  
from Savient Pharma Holdings, Inc.  
to INGLEBY (1705) Limited**

[PLEASE SEE NEXT PAGE]

SAVIENT FILE NO	TITLE	CTY	SERIAL NO	TYPE	FILING DT	PRIORITY DT	STATUS	ISSUE DT	PATENT NUMBER
ROS1993-0601-SE	ORAL LIQUID MEDICINE SOLUTION	SE	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	98202077-8
ROS1997-0601-AT	ORAL LIQUID MEDICINE SOLUTION	AT	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	AT 214269
ROS1997-0601-BE	ORAL LIQUID MEDICINE SOLUTION	BE	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-CH*	ORAL LIQUID MEDICINE SOLUTION	CH	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-CY	ORAL LIQUID MEDICINE SOLUTION	CY	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-DE	ORAL LIQUID MEDICINE SOLUTION	DE	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	DE 69804169-0
ROS1997-0601-DK	ORAL LIQUID MEDICINE SOLUTION	DK	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	DK 0893121
ROS1997-0601-ES	ORAL LIQUID MEDICINE SOLUTION	ES	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	ES 2174388
ROS1997-0601-FI	ORAL LIQUID MEDICINE SOLUTION	FI	98202077.8	Utility	23-Jun-98	23-Jun-98	Issued	13-Mar-02	893121
ROS1997-0601-FR	ORAL LIQUID MEDICINE SOLUTION	FR	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-GB	ORAL LIQUID MEDICINE SOLUTION	GB	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	EP (UK) 893121
ROS1997-0601-GR	ORAL LIQUID MEDICINE SOLUTION	GR	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	3039653
ROS1997-0601-IE	ORAL LIQUID MEDICINE SOLUTION	IE	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121

SAVIENT FILE NO	TITLE	CTY	SERIAL NO	TYPE	FILING DT	PRIORITY DT	STATUS	ISSUE DT	PATENT NUMBER
ROS1997-0601-IT	ORAL LIQUID MEDICINE SOLUTION	IT	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-JP	ORAL LIQUID MEDICINE SOLUTION	JP	10-176890	Utility	24-Jun-98		Pending		JP 11071269
ROS1997-0601-LU	ORAL LIQUID MEDICINE SOLUTION	LU	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-NL	ORAL LIQUID MEDICINE SOLUTION	NL	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	893121
ROS1997-0601-PT	ORAL LIQUID MEDICINE SOLUTION	PT	98202077.8	Utility	23-Jun-98	27-Jun-97	Issued	13-Mar-02	PT 893121
ROS1997-0601-US	ORAL LIQUID MEDICINE SOLUTION	US	09/106,172	Utility	26-Jun-98	27-Jun-97	Issued	3-Oct-00	6,127,425
ROS2006-0001-US1	LIQUID ORAL COMPOSITIONS	US	60/745,653	Prov	26-Apr-06		Pending		

\* This patent covers the territory of Liechtenstein